<DOC>
	<DOC>NCT01166282</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy and safety of adalimumab given subcutaneously every other week (eow) as compared to placebo in pediatric subjects with Enthesitis Related Arthritis (ERA).</brief_summary>
	<brief_title>A Study of the Efficacy and Safety of Adalimumab in Pediatric Subjects With Enthesitis Related Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Tendinopathy</mesh_term>
	<mesh_term>Arthritis, Juvenile</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Diagnosis of Enthesitis Related Arthritis (ERA) as defined by International League of Associations for Rheumatology (ILAR); Disease activity defined as at least 3 active joints and evidence of enthesitis in at least one location; Inadequate response or intolerance to at least one nonsteroidal antiinflammatory drug and at least one disease modifying antirheumatic drug, either sulfasalazine or methotrexate. Any ILAR Juvenile Idiopathic Arthritis (JIA) subtype other than ERA; Psoriasis or a history of psoriasis in the patient or firstdegree relative; Presence of Immunoglobulin M (IgM) rheumatoid factor; Presence of systemic JIA; History of inflammatory bowel disease; previous biologic therapy including antitumor necrosis factor (antiTNF) therapy with a potential impact on pediatric ERA; Infection(s) requiring treatment with IV antiinfectives within 30 days prior to Baseline or oral antiinfectives within 14 days prior to Baseline.</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>inflammatory back pain</keyword>
	<keyword>ankylosing spondylitis</keyword>
	<keyword>sacroiliitis</keyword>
	<keyword>Juvenile Idiopathic Arthritis</keyword>
	<keyword>enthesitis</keyword>
	<keyword>arthritis</keyword>
</DOC>